8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):    June 15, 2009

Medizone International, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Nevada

(State of Other Jurisdiction of Incorporation)

002-93277-D

 87-0412648

(Commission File Number)

(IRS Employer Identification No.)

144 Buena Vista, P.O. Box 742, Stinson Beach, California

    94970

(Address of Principal Executive Offices)

(Zip Code)

(415) 868-0300

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Item 7.01

Regulation FD Disclosure.

On June 15, 2009, Medizone International, Inc. (“the Company”) issued a press release announcing positive results from the second series of laboratory trials of the Company’s AsepticSure^TM hospital sterilization technology.

A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference.  The Company will also post this document on its corporate website, www.medizoneint.com, under the "Press Releases" link.

In accordance with General Instruction B.2 of Form 8-K, the information in this section of this Report shall not be deemed filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing.

Item 9.01.  Financial Statements and Exhibits.

(d)

Exhibits.  

99

Press Release dated June 15, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medizone International, Inc.

Date: June 15, 2009

By:  /s/ Edwin G. Marshall

     -----------------------------------------------

Edwin G. Marshall

Chairman of the Board and Chief Executive Officer

(Principal Executive Officer)

2

EX-99

EXHIBIT 99

Medizone Announces That Its AsepticSure(TM) Development Program is Reaching Objectives on Two Fronts

SAN FRANCISCO, June 15 /PRNewswire-FirstCall/ -- Early results from the second series of trials have demonstrated a 5 log reduction (99.999%) in Pseudomonas aeruginousa and a 4.4 log reduction (99.994%) in Methicillin Resistant Staph Aureus (MRSA). Both of these pathogens are of major concern to medical treatment facilities world wide with the spread of MRSA infection often being referred to as the "silent epidemic". The CDC reported (JAMA 2007) that MRSA alone is now associated with an estimated 19,000 deaths annually in the US. Dr. Michael E. Shannon, Medizone's Director of Medical Affairs commented, "Although the results from our first round of trials were very encouraging, introducing several procedural refinements in this second round resulted in levels of bactericidal action well above what was expected. Indeed, breaking through the 5 log barrier has led us to conclude that with a third technological development still to be introduced in this series of trials, the bactericidal ceiling for our system is now unclear, but well above what we ever expected. Needless to say, we are very excited over these findings and even more convinced that our new technologies will save hundreds of thousands of lives each year world wide. Add to the system's efficacy the fact that it will be safe, extremely cost effective and adaptable to virtually any situation anywhere, leads me to conclude that AsepticSure will have a global reach."

In parallel research recently conducted at BioZone Corporation, Medizone's engineering development partner, it was confirmed the AsepticSure(TM) hospital sterilization system can charge a room of 1,065 cubic feet to our target ozone level in less than 15 minutes, which is followed by the ozone decontamination phase. The same room can then be returned to a habitable standard (less than 0.02 ppm ozone) in 13 minutes using a separate ozone destruct technology. This confirms the start to finish time to complete the entire decontamination process can be achieved with minimal disturbance to normal hospital flow patterns. From a commercial viewpoint, the higher the "kill rate" in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.

Medizone International, Inc. (Pink Sheets: MZEI - News), is a research and development company engaged in developing its' AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. If current trials continue to proceed successfully they will be followed by a hospital mock-up and then hospital beta testing of the production prototype. Initial sales are targeted to commence in the 4th quarter of this year.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Investor Relations 800-953-3350 / web site: www.medizoneint.com

E-mail: operations@medizoneint.com